SpinCeutica, Inc. — Department of Health and Human Services SBIR Phase II: NIAID
SpinCeutica, Inc. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,188,095
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NIAID
- Solicitation
- PAR14-088
- NAICS
- —
- Place of performance
- NM
- Period
- 2017-03-06 → 2020-02-29
Description
Project Summary The overall goal of this project is to develop our new stable isotope labeledversion of an existing tuberculosisTBdrugisoniazidINHfor use in treated drug resistant TBWe hypothesize that our that isotope enhanced compound can be developed into a powerful new drug against INH resistant TB and multidrug resistant TBby addressing the following specific aimsSpecific AimDetermine what other INH resistance associated mutationsacylC INH can overcomeand determine the mechanism for whyacylC INH overcomes the high INH resistance of mutant ST KatG strainsSpecific AimDevelop an optimized synthesis of our compound and a Technology Transfer ProtocolTTPfor external good manufacturing processesGMP capable manufactureSpecific AimCollect non Good Laboratory PracticesGLPtoxicology data on our compound to support subsequent GLP Investigational New DrugINDenabling studiesSuccessful completion of these tasks will pave the way for venture capital funding and transfer of our compound into clinical testing